Clinical Trials Directory

Trials / Terminated

TerminatedNCT01548534

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer

A Phase III Randomized, Multicenter, Two Arms Double-blind Trial Versus Placebo, Evaluating the Interest of a Dietary Supplementation With Docosahexaenoic Acid (DHA) During Chemotherapy for Metastatic Breast Cancer

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
65 (actual)
Sponsor
University Hospital, Tours · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to increase, by DHA-induced chemosensitization, the activity of anticancer chemotherapy in patients with a metastatic advanced breast cancer, by a nutritional approach with marin-derived PolyUnsaturated Fatty Acids (PUFA).

Detailed description

Local relapses and metastases make breast cancer a deadly disease. A major goal remains the improvement of treatment efficacy, meaning increasing toxicity to tumor tissue, without additional toxicity to non-tumor tissues. The literature indicates that DHA sensitizes breast malignant tumors, but not non-tumor tissues, to chemotherapy and to radiotherapy through a variety of mechanisms. DHA enrichment of tissues can be achieved through a dietary supplementation of DHA-containing oils, such as fish oil, both in experimental animal models or in humans. Therefore, this represents an original nutritional approach to increase the activity of anticancer treatments through an enhanced specificity toward tumor tissues.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTDietary supplementation with fish oil.Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
DIETARY_SUPPLEMENTDietary supplementation with vegetable oilPatients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.

Timeline

Start date
2012-02-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2012-03-08
Last updated
2015-07-29

Locations

11 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01548534. Inclusion in this directory is not an endorsement.